APA (7th ed.) Citation

Zhu, Y., Liu, K., Zhu, H., Li, S., & Yuan, D. Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: A cost-effectiveness analysis. SAGE Publishing.

Chicago Style (17th ed.) Citation

Zhu, Youwen, Kun Liu, Hong Zhu, Shan Li, and Dan Yuan. Enfortumab Vedotin Plus Pembrolizumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: A Cost-effectiveness Analysis. SAGE Publishing.

MLA (9th ed.) Citation

Zhu, Youwen, et al. Enfortumab Vedotin Plus Pembrolizumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: A Cost-effectiveness Analysis. SAGE Publishing.